Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy

This randomized, double-blind, placebo-controlled clinical trial will investigate the effects of creatine supplementation combined with a 12-week supervised resistance training program on muscle mass, muscle strength, physical performance (e.g., parameters of sarcopenia), and muscle density in men with prostate cancer undergoing androgen deprivation therapy (ADT). ADT often causes loss of lean mass, reduced muscle strength, functional impairment, and increased fat mass. Eligible male patients will be randomly assigned to receive either creatine monohydrate or a placebo (maltodextrin) in a double-blind manner, in addition to participating in the resistance exercise program. Assessments will be performed at baseline and after the 12-week intervention period and will include: * Muscle density and architecture assessed by ultrasound * Body composition (lean mass and fat mass) * Muscle strength * Physical performance (functional performance tests) * Inflammatory biomarkers * Vascular function parameters The primary goal is to assess whether creatine supplementation combined with resistance training can safely improve muscle quality and quantity, strength, and physical function in these patients. If effective and safe, the intervention could help reduce muscle loss and improve quality of life in men undergoing ADT.

Sex

Male

Minimum age

40 Years

Inclusion Criteria:

* Men aged ≥ 40 years;
* Patients with histologically or cytologically confirmed localized prostate cancer;
* Patients who have undergone surgical castration or pharmacological castration with gonadotropin-releasing hormone (GnRH/LHRH) agonists or antagonists for at least six months prior to the start of the intervention;
* Patients receiving continuous or intermittent androgen deprivation therapy;
* Patients with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
* Not engaged in resistance training in the three months prior to the intervention;
* Not using creatine supplementation in the three months prior to the intervention;
* Willing to participate in a 12-week intervention consisting of resistance training performed three times per week and daily supplementation with creatine monohydrate or maltodextrin.

Exclusion Criteria:

* Patients with insulin-dependent diabetes mellitus;
* Patients with dialysis-dependent renal failure;
* Patients with severe chronic liver disease;
* Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m²;
* Any hormonal treatment outside that established by the medical team;
* Patients planning to undergo chemotherapy within the next six months.

• RESULTYuan F, Wang Y, Xiao X, Zhang X, Jing M, Kamecki H, Tan YG, Barreras SG, Aragon-Ching JB, Ma Z, Zhang P, Chang D, You Y. A systematic review evaluating the effectiveness of exercise training on physical condition in prostate cancer patients undergoing androgen deprivation therapy. Transl Androl Urol. 2023 Aug 31;12(8):1336-1350. doi: 10.21037/tau-23-272. Epub 2023 Aug 4. PMID 37680229
• RESULTMcTiernan A, Friedenreich CM, Katzmarzyk PT, Powell KE, Macko R, Buchner D, Pescatello LS, Bloodgood B, Tennant B, Vaux-Bjerke A, George SM, Troiano RP, Piercy KL; 2018 PHYSICAL ACTIVITY GUIDELINES ADVISORY COMMITTEE*. Physical Activity in Cancer Prevention and Survival: A Systematic Review. Med Sci Sports Exerc. 2019 Jun;51(6):1252-1261. doi: 10.1249/MSS.0000000000001937. PMID 31095082
• RESULTKovac MB, Pavlin T, Cavka L, Ribnikar D, Spazzapan S, Templeton AJ, Seruga B. The trajectory of sarcopenia following diagnosis of prostate cancer: A systematic review and meta-analysis. J Geriatr Oncol. 2023 Sep;14(7):101594. doi: 10.1016/j.jgo.2023.101594. Epub 2023 Jul 22. PMID 37482497